Atara Biotherap (NQ: ATRA )

13.50 USD -0.63 (-4.46%)

Streaming Delayed Price Updated: 11:32 AM EDT, Oct 28, 2020 Add to My Watchlist

Price and Volume

Volume	72,976
Open	13.78
Bid (Size)	13.44 (2)
Ask (Size)	13.53 (6)
Prev. Close	14.13
Today's Range	13.30 - 13.79
52wk Range	4.520 - 19.36
Shares Outstanding	43,949,486
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Atara Biotherapeutics To Present Clinical Data in Epstein-Barr Virus-Driven (EBV+) Acquired & Primary Immunodeficiency Lymphoproliferative Diseases (AID-LPD and PID-LPD) from Tab-Cel® Expanded Access

September 14, 2020

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases...

Atara Biotherapeutics Announces All Progressive Multiple Sclerosis Patients with Sustained Disability Improvement at Six Months Confirmed Improvement at 12 Months in the Phase 1a Study of ATA188

September 11, 2020

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases, including...

Performance

YTD	-17.73%	-17.73%
1 Month	+4.33%	+4.33%
3 Month	+4.57%	+4.57%
6 Month	+54.99%	+54.99%
1 Year	+9.76%	+9.76%

More News

Interesting ATRA Put And Call Options For June 2021

October 19, 2020

Atara Biotherapeutics Announces FDA Clearance of IND for ATA2271, a Next-Generation Autologous Mesothelin-Targeted CAR T with Novel PD1DNR and 1XX Technologies Combined to Treat Solid Tumors

September 08, 2020

Interesting ATRA Put And Call Options For November 20th

September 18, 2020

Atara Biotherapeutics to Present 12-Month Data from All Four Cohorts in the Phase 1a Study of ATA188 in Progressive Multiple Sclerosis at MSVirtual2020

September 01, 2020

Atara Biotherapeutics Clears Technical Benchmark, Hitting 80-Plus RS Rating

Today 3:00 EDT

Stocks With Rising Relative Strength: Atara Biotherapeutics

October 13, 2020

Atara Biotherapeutics Announces Second Quarter 2020 Financial Results and Operational Progress

August 05, 2020

Thinking about buying stock in CleanSpark, Atara Biotherapeutics, FuelCell Energy, Sorrento Therapeutics, or Plug Power?

September 11, 2020

Stocks Showing Market Leadership: Atara Biotherapeutics Earns 92 RS Rating

September 16, 2020

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.